CPHI vs GS · rev $4.1M vs P/E 20, $324.25B cap
China Pharma Holdings Inc (CPHI) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
China Pharma Holdings Inc (CPHI) is a drug manufacturers - specialty & generic company listed on US.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Latest reported CPHI revenue for 2025-12-31 was $4.1M. Net income was -$3.2M. Revenue was down 8.5% from 2024-12-31 to 2025-12-31. CPHI currently screens at market cap $29.0M.
GS does not have a complete income-statement cache yet.
CPHI currently screens at market cap $29.0M. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the CPHI and GS stock pages for the full models.
Not investment advice.